Company Overview of Sandoz International GmbH
Sandoz International GmbH develops, manufactures, and markets generic pharmaceutical products. It offers biosimilar, oncology injectable, respiratory, anti-infective, and biotechnological products, as well as medicines for various therapeutic areas, such as cardiovascular systems, central nervous systems, alimentary tracts and metabolisms, antineoplastic and immunomodulation agents, respiratory systems, and blood and blood forming organs. The company also offers drugs for suppressing recurrence of ischemic cerebrovascular disorder, lowering cholesterol, and preventing organ transplant rejection (kidney, liver, heart, lung, pancreas, and small intestine). It serves customers in Germany and in...
Key Executives for Sandoz International GmbH
Head of North American Operations and President of Sandoz US
Head of Legal and General Counsel
Head of Central & Eastern Europe, Middle East and Africa
Compensation as of Fiscal Year 2015.
Sandoz International GmbH Key Developments
Sandoz Licenses its Biosimilar Rituximab to Kyowa Hakko Kirin Co., Ltd in Japan
Jan 25 16
Sandoz announced that it has entered into an exclusive license agreement with Kyowa Hakko Kirin Co., Ltd. for the distribution and promotion of its biosimilar rituximab - a monoclonal antibody, in Japan. Under the terms of the agreement, Sandoz will file for marketing authorization of biosimilar rituximab and its manufacture if approved. Kyowa Hakko Kirin will be responsible for all sales, marketing and promotion activities in Japan. Kyowa Hakko Kirin will pay Sandoz an up-front fee, subsequent payments for regulatory filing, regulatory approval, success-based milestones, royalties as well as defined supply price for every order.
Sandoz International GmbH Presents at BIO-Europe 2015, Nov-02-2015
Oct 9 15
Sandoz International GmbH Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Sandoz Launches ZarxioTM (Filgrastim-Sndz), the First Biosimilar in the United States
Sep 3 15
Sandoz International GmbH announced that Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the US. Sandoz understands the importance of providing comprehensive patient support services in the oncology setting. With the launch of Zarxio, Sandoz is also proud to offer Sandoz One SourceTM a patient services center, providing support that connects the patient to the information and resources they need. The launch follows the FDA approval of Zarxio on March 6, 2015. The approval, via the new biosimilars pathway established under the Biologics Price Competition and Innovation Act, was based on a comprehensive package of analytical, nonclinical, and clinical data, which confirmed that Zarxio is highly similar with no clinically meaningful differences to the US-licensed reference product. The successful Sandoz pivotal head-to-head PIONEER study was the final piece of data contributing to the totality of evidence used by FDA to approve Zarxio as biosimilar to the reference product. Importantly, the data demonstrating high similarity was sufficient to allow extrapolation of use of Zarxio to five indications of the reference product.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|